Colorado Prescription Drug Affordability Review Board & Advisory Council
To receive PDAB and PDAAC updates directly in your inbox, click the button below. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175, is a Type-1 Board within the Division of Insurance that will have the authority to review prescription drug costs and evaluate their impact on Coloradans. The Board may then recommend ways to address those costs and may set an upper payment limit for certain drugs. The Board has appointed a multi-stakeholder Advisory Council to provide input to the Board to ensure its work is informed by a variety of stakeholders.
PDAB Meeting: Friday, June 23 at 10 am MT
Register for June 23 PDAB Meeting
PDAAC Meeting & Dashboard Walkthrough: Friday, June 9 at 1 pm MT
Register for June 9 PDAAC Meeting
Stakeholder Meeting: Wednesday, June 14 at 5:30 pm MT
Questions & Accessibility
Questions about the Prescription Drug Affordability Board and Advisory Council can be sent to firstname.lastname@example.org.
We are committed to providing equal access to our meetings for all participants. If you would like to request an accommodation to attend a Board or Advisory Council meeting, please contact us at email@example.com with your request by the close of business at least one week in advance of a meeting.
About PDAB & PDAAC
The Prescription Drug Affordability Board (PDAB) is a 5 member Type-1 Board tasked with the following statutory duties:
- Identify drugs that may be subject to an affordability review;
- Conduct affordability reviews on selected eligible drugs;
- Determine whether a prescription drug is unaffordable for Colorado consumers;
- If a drug is found to be unaffordable, the Board may set an upper payment limit;
- Make policy recommendations to the General Assembly.
- PDAB Materials
- Board Members
The Governor appointed the following Prescription Drug Affordability Board Members on September 27, 2021:
- Sami Diab, MD of Greenwood Village, Colorado
- Amarylis “Amy” Gutierrez, PharmD of Aurora, Colorado
- Catherine Harshbarger of Holyoke, Colorado
- Gail Mizner, MD, FACP, AAHIVS of Snowmass Village, Colorado and to serve as Board Chair
- James Justin VandenBerg, PharmD, BCPS of Denver, Colorado
The Board appointed the 15 member Prescription Drug Affordability Advisory Council (PDAAC) to provide stakeholder input on prescription drug affordability. All PDAAC members meet statutory requirements for composition, geographic representation, and subject matter expertise.
To the extent possible, the Board appointed members who have experience serving underserved communities and who reflect the state’s diversity in terms of race, immigration status, income, disability, age, gender identity, and geography.
- PDAAC Materials
- Council Members
- Kim Bimestefer Executive Director of HCPF
- Gail deVore representing health care consumers
- Sarita Parikh representing health care consumers
- Edward A. Dauer, LL.B., M.P.H. representing statewide health care advocacy organizations
- Kimberley Jackson, DO representing consumers with chronic diseases and PDAAC Chair
- Maria Fenwick representing a labor union
- Nathan Wilkes representing employers
- Chad Friday representing carriers
- Marc Reece representing pharmacy benefit managers
- Thomas Tobin, MD, MBA representing health care professionals with prescribing authority
- R. Brett McQueen, PhD representing an organization that researches prescription drugs
- Katelin Lucariello MPH representing manufacturers of brand name drugs
- Neal Miller representing manufacturers of generic drugs
- Andrew Gonzales, PharmD representing pharmacists
- Jason Atlas, RPh, MBA representing wholesalers
- Learning Series & Resources
Slides and recordings for the five part Prescription Drug Affordability Learning Series can be found below.
Learning Series 1: Data Deep Dive
Learning Series 2: Patient Perspectives
Learning Series 3: Pharmaceutical Supply Chain Panel
View Pharmaceutical Supply Chain Panel
Learning Series 4: Comparative Effectiveness & Affordability
View Comparative Effectiveness & Affordability
Learning Series 5: Prescription Drug Affordability Efforts in Colorado & Other States
View Prescription Drug Affordability Efforts in Colorado & Other States
Reducing Prescription Drug Costs in Colorado, 2nd Edition
CIVHC Top 100 Brand and Generic Commercial Payer Prescription Drugs
- Conflict of Interest Information
PDAB's Conflict of Interest Policy
Information required to be disclosed pursuant to §10-16-1402(3)(d) will be contained here.